IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.91
+0.58%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.18
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 7, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.17
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -15.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $22
- PT range
- $19 – $27
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026